oligonucleotide

(redirected from Oligos)
Also found in: Medical, Encyclopedia.

ol·i·go·nu·cle·o·tide

 (ŏl′ĭ-gō-no͞o′klē-ə-tīd, -nyo͞o′-, ō′lĭ-)
n.
A short polymer of two to twenty nucleotides.

oligonucleotide

(ˌɒlɪɡəʊˈnjuːklɪəˌtaɪd)
n
(Biochemistry) a polymer consisting of a small number of nucleotides

ol•i•go•nu•cle•o•tide

(ˌɒl ɪ goʊˈnu kli əˌtaɪd, -ˈnyu-)

n.
a chain of a few nucleotides.
[1940–45]
References in periodicals archive ?
Oligos are essential for development of new clinical genetic tests, target enrichment in panel tests, primers for qPCR-based tests, and barcoding samples to enable multiplexing.
AUMsilence self-delivering oligos achieve highly efficient and potent antisense-based gene knockdown.
Tenders are invited for Purchase of Desalted Oligos, 25 nmol tube format per base 3000 Integrated DNA
Locked Nucleic Acid oligos are claimed to provide dramatically improved sensitivity and specificity compared to traditional DNA chemistries.
The synthesized oligonucleotides segment is expected to register the highest growth rate in the oligonucleotide synthesis market during the forecast period, owing to an increasing number of applications for synthesized oligonucleotides in research, diagnostics and therapeutics; and a growing demand for custom oligos.
Users can specify the premixing of 2 - 6 standard desalted DNA oligos, in a single tube, according to the individual specifications provided.
New equipment includes 4 AKTA OligoPilots each capable of producing oligos from 500 umole to 50g scale of oligo per run.
United States patent 6,429,199 entitled "Immunostimulatory nucleic acid molecules for activating dendritic cells" relates to the use of CpG oligos which have a specific nucleotide sequence, including at least one unmethylated CpG dinucleotide, to stimulate potent antigen-presenting cells.
The Degussa Group, Dusseldorf, Germany, will acquire Genset Oligos, the oligonucleotide division of Genset S.
Design of capture and reporter oligos incorporates a base-stacking technology.
Two types of glial cells are familiar to people who read up on MS--the astrocytes, which normally support the nerve-cell fibers or axons, and the oligodendrocytes, oligos for short, which produce that essential myelin.
In the future, 10 years from now, the whole area of using oligos instead of small proteins as drugs will be much more common, and in the long run this approach will be a lot more efficacious.